Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00417716
- Phase
- PHASE3
- Status
- Withdrawn
Conditions
- Diabetes Mellitus Type 2
- Diabetic Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 45 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal Bevacizumab — DRUG
Study Details
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Key Dates
- First listed
- Jan 4, 2007
- Start date
- Sep 30, 2005
- Status verified
- May 2024
- Primary completion
- Sep 30, 2005
- Completion
- May 31, 2006
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
BCVA
Related Studies
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaPHASE1/PHASE2 · Recruiting · Eclipse Life Sciences, Inc. · Tampa, Florida
- PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAGRecruiting · Aventusoft, LLC. · West Palm Beach, Florida
- Iowa Produce Prescription ProgramEnrolling By Invitation · Iowa State University · Ames, Iowa